Lundbeck Offloads Assets to Three Partners as It Exits 27 Markets, Leaving 602 Jobless

Lundbeck has announced it will withdraw from 27 markets, transferring commercial operations in those countries to three partners:
Swixx Group, Zuellig Pharma, and NewBridge Pharmaceuticals23.

This strategic retreat results in 602 job losses as the company shifts to a partnership-based model in the affected territories, which include areas across Asia, Europe, South America, North Africa, and the Middle East23.

The markets affected accounted for about 12% of Lundbeck’s 2024 revenue3.

The decision is aimed at reducing operational complexity and reallocating resources to focus on high-growth and specialty disease areas, particularly in neuro-rare and neuro-specialty disease franchises3.

Lundbeck will continue operating directly in over 20 markets such as the U.S., U.K., China, Japan, Canada, and Korea, which generate the majority of its earnings3.

The restructuring is expected to incur a one-time charge of approximately 390 million Danish Krone (around $61 million), with no impact on the 2025 financial guidance3.

Lundbeck reported a 14% year-on-year revenue growth in the first half of 2025, largely driven by strategic brands like Rexulti3.

Sources:

2. https://ground.news/article/lundbeck-retreats-from-dozens-of-markets-slashing-staff_9a5cf6

3. https://www.biospace.com/business/lundbeck-offloads-assets-to-three-partners-as-it-exits-27-markets-leaving-602-jobless